Genetic variants of the SARS-CoV-2 virus are emerging but so far do not seem to have caused breakthrough infections in people with previous infection or in those who have been vaccinated. John P. Moore, PhD, of Weill Medical College of Cornell University in New York, joins JAMA's Q&A series for an update on the latest variants and what you need to know. Recorded March 4, 2021.

Related Article:

Approaches for Optimal Use of Different COVID-19 Vaccines

Interview with Christopher J.L. Murray, MD, DPhil, author of The Potential Future of the COVID-19 Pandemic: Will SARS-CoV-2 Become a Recurrent Seasonal Infection?

Related Article(s):

The Potential Future of the COVID-19 Pandemic

Interview with James C. Robinson, PhD, author of Funding of Pharmaceutical Innovation During and After the COVID-19 Pandemic

Nancy E. Messonnier, MD is director of the National Center for Immunization and Respiratory Diseases (NCIRD) at the Centers for Disease Control and Prevention (CDC) and leads the CDC's efforts on COVID-19 vaccination. She joins JAMA's Q&A series to discuss the agency's response to emerging coronavirus variants, the FDA advisory hearings on the new Johnson & Johnson vaccine, and other agency activities and priorities related to COVID-19 control. Recorded February 26, 2021.

Related Content:

• Genetic Variants of SARS-CoV-2—What Do They Mean?
• Coronavirus Vaccine Update From the CDC With Nancy E. Messonnier, MD
• SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants
• Experts Discuss COVID-19—Vaccine Doses, Virus Variants, and More
• Emergence of a Novel SARS-CoV-2 Variant in Southern California
• SARS-CoV-2 Variants of Concern in the United States
• Pregnant People Getting Mixed Messages About COVID-19 Vaccines
• The Johnson & Johnson Vaccine for COVID-19
• SARS-CoV-2 Viral Variants—Tackling a Moving Target
• Vaccine Distribution—Equity Left Behind?
• Taking Vaccine to Where the Virus Is—Equity and Effectiveness in Coronavirus Vaccinations?

The Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines are the first of many being tested for widespread use. Buddy Creech, MD, MPH, director of the Vanderbilt Vaccine Research Program, reviews these and other vaccines likely to become available, including products that use inactivated, protein subunit, and viral vector immunization strategies.

Related Article(s):

SARS-CoV-2 Vaccines

The CDC coordinated a massive effort to immunize nearly all nursing home and long-term care facility residents in the US against COVID-19 infection in the month after vaccine approval. Ruth Link-Gelles, PhD, MPH, CDC staff epidemiologist and Lieutenant Commander of the US Public Health Service Commissioned Corps, describes how.

Related Article(s):

• First-Dose COVID-19 Vaccination Coverage Among Skilled Nursing Facility Residents and Staff
• Nursing Homes' Next Test—Vaccinating Workers Against COVID-19

Researchers Investigate What COVID-19 Does to the Heart; "Important Conversations" Are Needed to Explain the Nocebo Effect; Therapists Donate Their Time to Counsel Distressed Health Care Workers

Related Article:

Researchers Investigate What COVID-19 Does to the Heart

"Important Conversations" Are Needed to Explain the Nocebo Effect

Therapists Donate Their Time to Counsel Distressed Health Care Workers

CDC Director Rochelle P. Walensky, MD, MPH, returns to JAMA's Q&A series to discuss the agency's response to emerging SARS-CoV-2 variants, implications for the planned vaccine mobilization strategy, the upcoming Johnson & Johnson vaccine FDA advisory hearings, strategies for reopening K-12 schools, and other agency activities and priorities related to COVID-19 control. Recorded February 17, 2021.

Related Article(s):

• Coronavirus Update With CDC Director Rochelle Walensky - February 17, 2021
• SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities
• SARS-CoV-2 Viral Variants—Tackling a Moving Target

Paul A. Offit, MD, of The Children's Hospital of Philadelphia returns to JAMA's Q&A series to provide an update on the emergence of COVID-19 variants and their implications for vaccine development, including the Johnson & Johnson vaccine, scheduled for a US Food and Drug Administration VRBPAC hearing on February 26, 2021. Recorded February 11, 2021.

Related Article:

SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants

Natural experiments comparing coronavirus spread on ships and in hair salons with vs without face masks point to the importance of wearing masks for curbing SARS-CoV-2 spread. John T. Brooks, MD, chief medical officer of the CDC's COVID-19 response team, reviews recently published epidemiologic data that reinforce the role of mask use for pandemic control.

Related Article:

Effectiveness of Mask Wearing to Control Community Spread of SARS-CoV-2